Cart
sales@molnova.com
BMS-986122
CAS No. 313669-88-4
BMS-986122( BMS 986122 | BMS986122 )
Catalog No. M27859 CAS No. 313669-88-4
BMS 986122 is a positive allosteric modulator of μ-opioid receptors that increases β-arrestin recruitment stimulated by endomorphin 1 in U2OS-OPRM1 human osteosarcoma cells expressing μ-opioid receptors (EC50 = 3 μM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 87 | Get Quote |
|
| 10MG | 147 | Get Quote |
|
| 25MG | 327 | Get Quote |
|
| 50MG | 520 | Get Quote |
|
| 100MG | 745 | Get Quote |
|
| 500MG | 1485 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBMS-986122
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS 986122 is a positive allosteric modulator of μ-opioid receptors that increases β-arrestin recruitment stimulated by endomorphin 1 in U2OS-OPRM1 human osteosarcoma cells expressing μ-opioid receptors (EC50 = 3 μM).
-
DescriptionBMS 986122 is a positive allosteric modulator of μ-opioid receptors that increases β-arrestin recruitment stimulated by endomorphin 1 in U2OS-OPRM1 human osteosarcoma cells expressing μ-opioid receptors (EC50 = 3 μM).
-
In Vitro——
-
In Vivo——
-
SynonymsBMS 986122 | BMS986122
-
PathwayEndocrinology/Hormones
-
TargetOpioid Receptor
-
RecptorFAP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number313669-88-4
-
Formula Weight448.77
-
Molecular FormulaC16H15BrClNO3S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (222.83 mM)
-
SMILESCOc1ccc(cc1Br)C1SCCN1S(=O)(=O)c1ccc(Cl)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hui Jin Jung, et al. Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor. Bioorg Med Chem Lett. 2021 Apr 1;37:127846.
molnova catalog
related products
-
PL 017
Selective μ opioid receptor agonist (IC50 values are 5.5 and > 10000 nM for inhibition of 125I-FK 33,824 and 125I-DADLE binding to μ and δ sites respectively). Produces naloxone-reversible analgesia, catalepsy and hyperthermia following central administration in rats in vivo.
-
TAK-285
TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.
-
ORL1 antagonist 1
ORL1 antagonist 1 is an o antagonist of pioid receptor-like 1 (ORL1) (IC50 of 61 nM).
